Skip to main content

Petros Pharmaceuticals, Inc. (PTPI)

NASDAQ: PTPI · IEX Real-Time Price · USD
1.70 0.06 (3.66%)
Oct 21, 2021 4:00 PM EDT - Market closed
Market Cap23.34M
Revenue (ttm)12.93M
Net Income (ttm)n/a
Shares Out9.80M
EPS (ttm)-0.92
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,462,610
Open1.80
Previous Close1.64
Day's Range1.68 - 1.92
52-Week Range1.56 - 5.96
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 9, 2021

About PTPI

Petros Pharmaceuticals, Inc. engages in identifying, acquiring, developing, and commercializing therapeutics for men's health issues in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company develops H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. It also offers prescription medication, such as Stendra for the treatment of male erectile dysfunction; and vacuum erection devices. Petros Pharmaceuticals, Inc. is based...

IndustryDrug Manufacturers-Specialty & Generic
Founded2020
Employees27
Stock ExchangeNASDAQ
Ticker SymbolPTPI
Full Company Profile

Financial Performance

In 2020, PTPI's revenue was $9.56 million, a decrease of -38.63% compared to the previous year's $15.58 million. Losses were -$20.59 million, -36.68% less than in 2019.

Financial Statements

News

Petros Pharmaceuticals Announces Closing of $5.7 Million Registered Direct Offering

NEW YORK, Oct. 19, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced the closing of its previously announced register...

3 days ago - PRNewsWire

Petros Pharmaceuticals Announces $5.7 Million Registered Direct Offering

NEW YORK, Oct. 14, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announces that it has entered into definitive agreements w...

1 week ago - PRNewsWire

Petros Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

NEW YORK, Sept. 10, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Officer Fad...

1 month ago - PRNewsWire

Petros Pharmaceuticals Announces Second Quarter Financial Results and Provides Corporate Update; Reports a 123% Incre...

NEW YORK, Aug. 17, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced financial results fo...

2 months ago - PRNewsWire

Petros Pharmaceuticals to Present at Two Upcoming August Conferences

NEW YORK, Aug. 12, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced that President and Chief Commercial Officer Fady...

2 months ago - PRNewsWire

Petros Pharmaceuticals: Invitation to the Q3 Virtual Investor Summit

New Jersey and Pennsylvania--(Newsfile Corp. - August 11, 2021) - Petros Pharmaceuticals (NASDAQ: PTPI) today announced that Fady Boctor, President, Chief Commercial Officer will be attending the Q3 Vir...

2 months ago - Newsfile Corp

Petros Pharmaceuticals to Present at the Access to Giving Virtual Investor Conference on July 14, 2021

NEW YORK, July 12, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced that President and Chief Commercial Officer Fady...

3 months ago - PRNewsWire

Petros Pharmaceuticals to Present at the LD Micro Virtual Invitational Conference on June 10, 2021

NEW YORK, June 2, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced that President and Chief Commercial Officer Fady ...

4 months ago - PRNewsWire

Petros Pharmaceuticals Announces First Quarter Financial Results and Provides Corporate Update; Reports 300% increase...

NEW YORK, May 17, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Petros or the Company) (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced financial results for the...

5 months ago - PRNewsWire

Petros Pharmaceuticals to Participate at the Investor Summit Conference and Present to Investors on May 18, 2021

NEW YORK, May 14, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced that management will participate at the Investor ...

5 months ago - PRNewsWire

Neurotrope, Inc. Approves Spin-Off of Neurotrope Bioscience, Inc. and Sets Record and Distribution Dates

NEW YORK, Nov. 20, 2020 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP) ("Neurotrope" or the "Company") announced today that its Board of Directors has approved the conditional distribution and set the ...

11 months ago - PRNewsWire

Neurotrope Shareholders to Own 49 Percent of Petros Under Revised Merger Agreement with Metuchen

NEW YORK and MANALAPAN TOWNSHIP, N.J., Sept. 30, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company focused on innovati...

1 year ago - PRNewsWire

Neurotrope and Metuchen Pharmaceuticals Announce Merger Agreement to Form Petros Pharmaceuticals, a Men's Health Company

NEW YORK and MANALAPAN TOWNSHIP, N.J., May 18, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company ("Metuchen"), focused...

1 year ago - PRNewsWire

Neurotrope Rips 150% Higher On Improved Alzheimer's Data, NIH Funding

Shares of thinly-traded microcap biopharma Neurotrope Inc (NASDAQ: NTRP) gap-opened sharply higher on above 50 times average volume following a corporate update from the company.

1 year ago - Benzinga

Some Great News for Potential Alzheimer’s Treatment

It may be unusual to see a stock rise close to 100% without a corporate buyout, but in biotech and emerging pharmaceutical companies gains of that size can occur simply with a drug study update from eve...

1 year ago - 24/7 Wall Street

Neurotrope's stock plummets on heavy volume after disappointing trial of Alzheimer's treatment

Shares of Neurotrope Inc. NTRP, -77.95% plummeted 79% on heavy volume Monday, to below the $1 mark for the first time in six years, after the biopharmaceutical company said its Alzheimer's disease (AD) ...

2 years ago - Market Watch

Why Neurotrope Is Plunging On Heavy Volume

Shares of thinly-traded nano-cap biotech Neurotrope Inc (NASDAQ: NTRP) were plummeting Monday following an adverse clinical trial readout.

2 years ago - Benzinga

Neurotrope Sees Hammer Chart Pattern: Time to Buy?

Neurotrope has been struggling lately, but the selling pressure may be coming to an end soon.

2 years ago - Zacks Investment Research

Is the Options Market Predicting a Spike in Neurotrope (NTRP) Stock?

Investors need to pay close attention to Neurotrope (NTRP) stock based on the movements in the options market lately.

2 years ago - Zacks Investment Research

Two Very Speculative Biotechs With Promising Alzheimer’s Treatment Hopefuls

The biotechnology sector is generally considered the most volatile and riskiest sector within all of healthcare.

Other symbols:AVXL
2 years ago - 24/7 Wall Street

Is Neurotrope the Default Alzheimer’s Winner After Biogen’s Implosion?

Neurotrope, Inc. may be a winner by default in the battle against Alzheimer’s disease after shares of Biogen Inc. suffered handily with the announcement that it and partner Eisei were halting late-stage...

2 years ago - 24/7 Wall Street